OF SHARED RESOURCE The purpose of the Cancer Functional Imaging Core at Johns Hopkins is to provide state-of-the art noninvasive imaging capabilities to Cancer Center members. Applications that are currently available using magnetic resonance imaging and spectroscopy and radionuclide imaging span molecular, cellular, preclinical human tumor model studies and clinical imaging. The Core is currently in the process of installing a new 9.4T horizontal bore magnet. Small animal PET and SPECT imaging systems as well as a Xenogen optical and VisualSonics ultrasound imaging system are also available. This equipment is housed in a 2,400 sq. ft. small animal imaging facility in the Broadway Research Building (BRB) overseen by a full-time manager. These facilities form the Cancer Functional Imaging Core. To understand and exploit molecular pathways in cancer for therapeutic strategies, it is essential to detect and image the expression of these pathways, and determine the impact of this expression on function at the cellular level, as well in vivo. MR, radionuclide and optical techniques have a vast array of capabilities to characterize function. These imaging techniques are also easily translatable into the clinic, and are therefore compatible with 'bench to bedside'applications. Dr. Zaver M. Bhujwalla is the Director of the Cancer Functional Imaging Core. She is also the director of the JHU ICMIC (In Vivo Cellular Molecular Imaging Center) Program and Associate Director of the JHU SAIRP (Small Animal Imaging Resource Program). Dr. Bhujwalla has an outstanding track record in MR molecular imaging applications in cancer. The two Associate Directors, Dr. Martin G. Pomper and Dr. Dmitri Artemov are well known investigators who have played a key role in the establishment ol Molecular Imaging at JHU. Dr. Pomper is also Director of the JHU SAIRP and Associate Director of the JHU ICMIC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117672
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$234,604
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications